11,934 reports of this reaction
2.9% of all ALPRAZOLAM reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for ALPRAZOLAM, manufactured by Viatris Specialty LLC. There are 11,934 FDA adverse event reports linking ALPRAZOLAM to FATIGUE. This represents approximately 2.9% of all 413,410 adverse event reports for this drug.
Patients taking ALPRAZOLAM who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for ALPRAZOLAM, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for ALPRAZOLAM:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 11,934 FDA reports for ALPRAZOLAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.9% of all adverse event reports for ALPRAZOLAM, making it one of the most commonly reported side effect.
If you experience fatigue while taking ALPRAZOLAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.